J Gill

Doxycycline pre-exposure prophylaxis (doxyPrEP) versus doxycycline post-exposure prophylaxis (doxyPEP) for preventing bacterial sexually transmitted infections in gay, bisexual, and other men who have sex with men (GBM) and transgender women: protocol for a randomized non-inferiority trial

Maya Tharp, Mark Hull, Ann N. Burchell, Darrell H. Tan et autres

The global incidence of bacterial sexually transmitted infections (STIs), including syphilis, gonorrhea, and chlamydia, is rising at an unprecedented rate. This trend is particularly concerning among gay, bisexual, and other men who have sex with men (GBM) and transgender women, who experience …

ca, us, th (code pays fourni par la source)

Temporal trends in viral setpoint and peak CD4+ cell count soon after HIV-1 seroconversion

Nikos Pantazis, Caroline Sabin, Dominique Costagliola, Sophie Grabar et autres

OBJECTIVES: To examine whether HIV-1 virulence, as measured by prognostic markers soon after seroconversion, has changed over time and across subgroups in the context of widespread ART availability. DESIGN: Observational cohort study of individuals with well estimated HIV-1 seroconversion dates recruited from …

gr, gb, fr, se, ca, nl, es (code pays fourni par la source)

The risk of HIV and HCV transmission in Canadians living with coinfection before, during, and after the COVID pandemic: A prospective cohort study

Jim Young, Shouao Wang, Matthew J. Knight, Claudette Cardinal et autres

ca (code pays fourni par la source)

Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study

Sarah Pett, Janaki Amin, A Horban, Jaime Andrade-Villanueva et autres

BACKGROUND: Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy …

au, gb, mx, ar, ca, jp, cl, es, th, fr, de, ie (code pays fourni par la source)

Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America

Peter F. Rebeiro, Peter F. Rebeiro, Keri N. Althoff, Bryan Lau et autres

Because of limitations in the availability of data on primary care encounters, patient retention in human immunodeficiency virus (HIV) care is often estimated using laboratory measurement dates as proxies for clinical encounters, leading to possible outcome misclassification. This study included 83,041 HIV-infected …

us (code pays fourni par la source)

Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery

Frederik Neess Engsig, Frederik N. Engsig, Όλγα Κατσαρού, Olga Katsarou et autres

BACKGROUND: Some human immunodeficiency virus (HIV)-infected individuals initiating combination antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but not CD4 cell recovery. We aimed to identify (1) risk factors for failure to achieve CD4 count >200 cells/µL after 3 years …

dk, at, gr, fr, nl, ca, gb, de, es, us, it, ch, be (code pays fourni par la source)

Long‐term probability of detecting drug‐resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection

Sara Lodi, Claudia Kücherer, AM Bakken Kran, Bernard Masquelier et autres

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK

gb, de, no, fr, it, ca (code pays fourni par la source)

Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide☆

Mona Loutfy, J. Raboud, Joan Montaner, Tony Antoniou et autres

ca (code pays fourni par la source)

Etiology and Natural History of Neutropenia in Human Immunodeficiency Virus Disease: A Prospective Study

David Moore, T. Benepal, Simon Portsmouth, J Gill et autres

The objective of this prospective, observational study was to define the natural history of neutropenia in human immunodeficiency virus (HIV) disease. Eighty-seven consecutive patients developing neutropenia (absolute neutrophil count [ANC], <1000 cells/mm(3)) were recruited and closely followed for the duration of the …

gb (code pays fourni par la source)

O18 A dichotomy in CD4 T‐cell responses specific to HIV antigens

Fm Gotch, Nesrina Imami, J Gill, Mike Westby et autres

Objective: We sought to compare HIV antigen-induced intracellular cytokine production and proliferation in a cohort of long-term nonprogressor (LTNP) patients and individuals with active/progressive (A/P) HIV disease. Methods: Seven LTNP patients and five patients with A/P disease were tested by incorporation of …

gb (code pays fourni par la source)

Cidofovir for the treatment of Kaposi's sarcoma in an HIV-negative homosexual man

Kate Fife, J Gill, Dimitra Bourboulia, Brian Gazzard et autres

S ir, Human herpesvirus 8 (HHV‐8) has been detected in the lesions of all forms of Kaposi’s sarcoma (KS) 1 and has been implicated as a probable causative agent. 2 This has led to interest in the use of antiviral drugs in …

in, gb (code pays fourni par la source)

Human immunodeficiency virus and acute fulminant infection

DN Lucas, Neelesh Soni, J Gill, M Nelson

The complications of human immunodeficiency virus (HIV) infection can result in life-threatening dysfunction requiring support in the intensive careunit (ICU). HIV is frequently overlooked as part of the differential diagnosis in those presenting with acute life-threatening infection. Consideration of the possibility of …

gb (code pays fourni par la source)